Image from the Drugs for Neglected Diseases Initiative
Today, the Drugs for Neglected Diseases Initiative (DNDi) announced in a press release that thirteen countries in Africa, along with an international network of research institutions, are launching the largest clinical trial in Africa for mild-to-moderate patients. DNDi is a global non-profit drug research and development (R&D) group that has extensive partnerships in Africa.
“We welcome the ANTICOV trial led by African doctors because it will help answer one of our most pressing questions: With limited intensive care facilities in Africa, can we treat people for COVID-19 earlier and stop our hospitals from being overwhelmed?’ – Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention.
The purpose of the ANTICOV trial is to identify early treatments that can prevent the progression of COVID-19 to a severe form of the disease, potentially limiting its transmission. Read more about the trial and institutions participating in the novel effort here.